Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18)

Circulation

Volumn 100, Issue 14, 1999, Pages 1533-1539

  Peter, Karlheinz ^a   Schwarz, Meike ^b   Conradt, Christian ^b   Nordt, Thomas ^b   Moser, Martin ^b   Kübier, Wolfgang ^b   Bode, Christoph ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NONE

Author keywords

Cell adhesion molecules; Fibrinogen; Heparin; Leukocytes

Indexed keywords

BLOOD CLOTTING FACTOR 10; CD11B ANTIGEN; FIBRINOGEN; HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

EID: 0033527375     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.14.1533     Document Type: Article

References (33)

1. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
2. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337: 688-698.
3. Rogers C, Welt FGP, Karnovsky MJ, Edelman ER. Monocyte recruitment and neo-intimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler Thromb Vasc Biol. 1996;16:1312-1318.
4. Coombe DR, Watt SM, Parish CR. Mac-1 (CD11b/CD18) and CD45 mediate the adhesion of hematopoietic progenitor cells to stromal cell elements via recognition of stromal heparan sulfate. Blood. 1994;84: 739-752.
5. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. Heparin is an adhesive ligand for the leukocyte integrin Mac-1. J Cell Biol. 1995; 130:1473-1481.
6. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994;76:301-314.
7. Hynes RO. Integrins: versatility, modulation, and signalling in cell adhesion. Cell 1992;69:11-21.
8. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: an alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA. 1988;85:7462-7466.
9. Altieri DC, Edgington TS. The saturable high affinity association of factor X to ADP-stimulated monocytes defines a novel function of the Mac-1 receptor. J Biol Chem. 1988;263:7007-7012.
10. Altieri DC, Etingin OR, Fair DS, Brunck TK, Geltosky JE, Haijar DP, Edgington TS. Structurally homologous ligand binding of integrin Mac-1 and viral glyco-protein C receptors. Science. 1991;254:1200-1202.
11. Plescia J, Altieri DC. Activation of Mac-1 (CD11b/CD18)-bound factor X by released cathepsin G defines an alternative pathway of leukocyte initiation of coagulation. Biochem J. 1996;319:873-879.
12. Altieri DC, Bader R, Mannucci PM, Edgington TS. Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol. 1988;107:1893-1900.
13. Wright SD, Weitz JI, Huang AJ, Levin SM, Silverstein SC, Loike JD. Complement receptor type 3 (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA. 1988;85:7734-7742.
14. Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE, Altieri DC. Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell. 1993;73:1-20.
15. 2 integrin CR3 (CD11b/CD18). Proc Natl Acad Sci USA. 1994;91:10680-10684.
16. Vétvička V, Thornton BP, Ross GD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest. 1996;98:50-61.
17. Benimetskaya L, Loike JD, Khaled Z, Loike G, Silverstein SC, Cao L, El Khoury J, Cai T, Stein CA. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat Med. 1997;3:414-420.
18. 3) inhibitors. Blood. 1998;92 3240-3249.
19. SAS Institute Inc. SAS/GRAPH Software. Version 6. Cary, NC: SAS Institute Inc; 1990.
20. Diamond MS, Garcia-Aguilar J, Bickford JK, Corbi AL, Springer TA. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J Cell Biol. 1993;120: 1031-1043.
21. Zhou L, Lee DH, Plescia J, Lau CY, Altieri DC. Differential ligand specificities of recombinant CD11b/CD18 integrin I-domain. J Biol Chem. 1994;269:17075-17079.
22. Coller BS. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J Clin Invest. 1997;99:1467-1471.
23. Altieri DC, Edgington TS. A monoclonal antibody reacting with distinct adhesion molecules defines a transition in the functional state of the receptor CD11b/CD18 (Mac-1). J Immunol. 1988;141:2656-2660.
24. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NV. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 1997;17:528-535.
25. 3 monoclonal antibody 7E3 and its involvement in leukocyte adherence. J Biol Chem. 1998;273:20372-20377.
26. Ott I, Neumann FJ, Gawaz M, Schmitt M, Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 1996;94:1239-1246.
27. Jude B, Agraou B, McFadden EP, Susen S, Bauters C, Lepelley P, Vanhaesbroucke C, Devos P, Cosson A, Asseman P. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina. Circulation. 1994;90:1662-1668.
28. Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, Bramucci E, Angoli L, Marsico F, Specchia G. Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease. Circulation. 1993;88:358-363.
29. De Servi S, Mazzone A, Ricevuti G, Fioravanti A, Bramucci E, Angoli L, Specchia G. Granulocyte activation after coronary angioplasty in humans. Circulation. 1990;82:140-146.
30. Mickelson JK, Lakkis NM, Villarreal LG, Hughes BJ, Smith CW. Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease. J Am Coll Cardiol. 1996;28:345-353.
31. Ikeda H, Nakayuma H, Oda T, Kuwanok I, Yamaga A, Ueno T, Yoh M, Hiyamuta K, Koga Y, Toshima H. Neutrophil activation after percutaneous transluminal coronary angioplasty. Am Heart J. 1994;128: 1091-1098.
32. Pietersma A, Kofflard M, de Wit EA, Stijnen T, Koster JF, Serruys PW, Sluiter W. Late lumen loss after coronary angioplasty is associated with the activation status of circulating phagocytes before treatment. Circulation. 1995;91:1320-1325.
33. Ma X, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest. 1991;88:1237-1243.